205 related articles for article (PubMed ID: 22781397)
1. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
Driscoll JJ; Chowdhury RD
Cancer Lett; 2012 Dec; 325(2):147-54. PubMed ID: 22781397
[TBL] [Abstract][Full Text] [Related]
2. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: targeting proteasomal protein degradation in cancer.
Molineaux SM
Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition as a novel therapeutic target in human cancer.
Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
[TBL] [Abstract][Full Text] [Related]
5. Cancer research. Taking garbage in, tossing cancer out?
Garber K
Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
[No Abstract] [Full Text] [Related]
6. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
7. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
8. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
[TBL] [Abstract][Full Text] [Related]
10. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
11. The proteasome and proteasome inhibitors in cancer therapy.
Voorhees PM; Orlowski RZ
Annu Rev Pharmacol Toxicol; 2006; 46():189-213. PubMed ID: 16402903
[TBL] [Abstract][Full Text] [Related]
12. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Min H; Xu M; Chen ZR; Zhou JD; Huang M; Zheng K; Zou XP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):167-76. PubMed ID: 24842158
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
15. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
17. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
18. [Proteasome inhibitors--new option in the treatment of tumor diseases].
Spicka I; Klener P
Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors as therapeutics.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
